4th Annual Obesity & Weight Loss Drug Development Summit

4th Annual Obesity & Weight Loss Drug Development Summit is organized by Hanson Wade and will be held from Jul 14 - 16, 2026 at Hotel Commonwealth Boston, Boston, Massachusetts, United States of America.

Description:
Developing Durable, Best-in-Class Therapies for Advancing Personalized, Next-Generation Drugs to Redefine Metabolic Quality & Accelerate the Shift From Acute Weight Loss to Sustainable Disease Modification.

The clinical success of GLP-1 receptor agonists marked a revolutionary first wave in metabolic medicine, fundamentally altering the treatment landscape for obesity. As we move through 2026, the market has entered a sophisticated new phase in which the focus has shifted from simple weight reduction to quality of weight loss, long-term maintenance, and patient-centric delivery. With the recent FDA approval of high-dose oral options and the debut of monthly maintenance injectables, the race for next-generation differentiation is no longer just about the scale, it’s about metabolic health, muscle preservation, and global accessibility.

The 4th Obesity & Weight Loss Drug Development Summit serves as the definitive industry meeting point. We are uniting 25+ expert speakers from pharma giants and innovative biotechs, including Novo Nordisk, Eli Lilly and Roche to strategically dissect the crucial challenges of muscle atrophy, treatment rebound, and the transition from injectables to next-gen orals.

Key Benefits of Attending:

• Join a high-impact workshop to navigate the evolving regulatory frontier and discover how to advance compounds by prioritizing functional endpoints and metabolic health over traditional weight-loss metrics, ensuring your pipeline aligns with the latest shifts in global clinical standards with Veru Inc.
• Delve into the science of revolutionizing combination and multi-agonist designs, including the integration of triple-agonists and GIP/GLP-1 synergies and learn directly from industry leaders
  like Novo Nordisk on how to push the ceiling of maximum weight loss potential while maintaining therapeutic safety
• Attend dedicated sessions on decoupling adipose tissue reduction from skeletal muscle atrophy and collaborate with Merck & Co. and SixPeaks Bio to prioritize muscle
  quality and function, transforming rapid weight loss into durable, long-term health outcomes that satisfy both patients and payers
• Explore the future of the market by investigating biological pathways beyond the incretin boom and gain firsthand insights from Scitherm Bio, Syntis Bio, and Energesis Pharmaceuticals on novel, nonGLP-1 modalities designed to offer more tolerable, post-treatment maintenance regimens and secure consistent payer support
• Participate in intensive sessions comparing injectable peptides against oral small molecules to determine the future of patient adherence and gain a competitive edge by learning how to balance peak potency with longterm convenience to dominate the burgeoning maintenance market with insights from CORXCEL Pharmaceuticals and Cirius Therapeutics

Join us at this unique, industry-led summit to:

• Assess the clinical outcomes and adherence benefits of oral small molecules versus ultra-long-acting injectables to gain a competitive edge by learning how to balance peak potency with the convenience required to dominate the burgeoning maintenance market with CORXCEL Pharmaceuticals and Cirius Therapeutics.
• Address the archaic reliance on BMI by exploring new FDAaligned clinical endpoints to learn to prioritize functional health and organ-specific metabolic recovery to secure regulatory approval and payer support in an increasingly crowded therapeutic landscape with Veru Inc.
• Tackle the critical challenge of “Sarcopenic Obesity” by delving into the science of decoupling adipose tissue reduction from skeletal muscle atrophy, ensuring patients lose fat, not strength, with specialized insights from SixPeaks Bio and Merck & Co.
• Master the evolution of Triple-Agonists (GLP-1/GIP/ Glucagon) and combination therapies and discover how to integrate these synergies to redefine the maximum weight loss potential while mitigating the side effects that often lead to treatment discontinuation with Novo Nordisk.
• Utilize genetics and proteomics to predict patient-specific responses, reducing the 15% “non-responder” rate currently seen in clinics to strategize on durable maintenance protocols that prevent post-treatment weight regain to ensure lifelong health outcomes with Canary Cure and Eli Lilly
• Join the 4th Obesity & Weight Loss Drug Development Summit and be part of the conversation that will define the second wave of metabolic innovation. Ensure your pipeline delivers not just rapid weight loss, but the sustainable, high-quality health outcomes that will define the next decade of medicine.

Key Topics:
Master the Evolving Regulatory Frontier
Prioritize functional metabolic health and "Quality of Weight Loss" to secure the next generation of best-in-class approvals.

Explore the Frontier of GIP/GLP-1/Glucagon Combinations
Redefine the ceiling of maximum weight loss potential and rival the efficacy of bariatric surgery.

Integrate Pediatric & Geriatric-Tailored Clinical Frameworks
Address the unique physiological risks in younger and older adults, such as sarcopenic frailty, to move beyond "undifferentiated weight loss" and achieve superior safety profiles and robust post-treatment maintenance for lifelong metabolic stability.

Delve Into the Science of Protecting Skeletal Muscle Quality
Ensure that rapid weight loss translates into functional longevity rather than physical frailty.

Navigate the Race Between Injectable Peptides & Oral Small Molecules
Balance peak potency with the long-term adherence required for life-long weight stability.